Keyphrases
Myeloproliferative Neoplasms
100%
JAK Inhibitors
100%
Pacritinib
100%
Janus Kinase 2 (JAK2)
75%
Colony Formation
50%
JAK-STAT
50%
Ancillary
50%
JAK2 Inhibitor
50%
Momelotinib
50%
RNA Sequencing (RNA-seq)
25%
In Vitro Model
25%
Patient-derived Xenograft
25%
Specific Inhibitor
25%
Disease Burden
25%
Phase II Study
25%
Leukemia
25%
FDA-approved Drugs
25%
Inflammatory Response
25%
Small Molecule Inhibitors
25%
Beneficial Effects
25%
Therapeutic Agents
25%
Therapeutic Efficacy
25%
Smad Signaling
25%
Engraftment
25%
Gene Set Enrichment Analysis
25%
Differential Effects
25%
Personalized Therapy
25%
RNA Genes
25%
Erythroid
25%
Mass Cytometry
25%
Antiproliferative Activity
25%
Clinical Profile
25%
Ruxolitinib
25%
Iron Regulation
25%
Hepcidin
25%
Response Signature
25%
Fedratinib
25%
Medicine and Dentistry
Myeloproliferative Neoplasm
100%
Janus Kinase Inhibitor
100%
Pacritinib
100%
Janus Kinase
75%
Colony Formation
50%
Janus Kinase 2 Inhibitor
50%
Momelotinib
50%
Cytokine
25%
Serositis
25%
RNA Sequence
25%
In Vitro
25%
Combination Therapy
25%
Disease Burden
25%
Personalized Medicine
25%
Therapeutic Agent
25%
Xenograft
25%
Engraftment
25%
Mass Cytometry
25%
Ruxolitinib
25%
RNA Gene
25%
Iron
25%
Hepcidin
25%
Fedratinib
25%
Genome-Wide Analysis of Gene Expression
25%
Pharmacology, Toxicology and Pharmaceutical Science
Myeloproliferative Neoplasm
100%
Janus Kinase Inhibitor
100%
Pacritinib
100%
Janus Kinase
75%
Janus Kinase 2 Inhibitor
50%
Momelotinib
50%
Combination Therapy
25%
Cytokine
25%
Inflammation
25%
RNA-Sequencing
25%
Ruxolitinib
25%
Iron
25%
Hepcidin
25%
Fedratinib
25%
Diseases
25%
Biochemistry, Genetics and Molecular Biology
Janus Kinase
100%
Janus Kinase Inhibitor
100%
Colony Formation
40%
Cytokine
20%
RNA Gene
20%
RNA Sequence
20%
Small Molecule
20%
SMAD
20%
Mass Cytometry
20%
Disease Burden
20%
Ruxolitinib
20%
Hepcidin
20%
Genome-Wide Analysis of Gene Expression
20%